Formulation Taste Masked Orodispersible Tablet of Pregabalin by Huda, Inderjeet singh Gurbachan singh & Toshniwal, Sanjay S.
  
 
International Journal of Drug Delivery 5 (2013) 56-62 
http://www.arjournals.org/index.php/ijdd/index 
 
Original Research Article 
             
Formulation taste masked orodispersible tablet of Pregabalin 
Inderjeet Singh G. Huda* 1, Sanjay S. Toshniwal 2 
 
*Corresponding author: 
 
Inderjeet Singh G. Huda 
 
1Research Scholar Bhagwant 
University Ajmer 
2 Dr. V. P. College of Pharmacy, Georai 
Tanda, Aurangabad ă 431005, M.S., 
India. 
 
 
 
 
 
 
 
A b s t r a c t  
In the present work, orodispersible tablets of Pregabalin were designed by preparing tasteless 
complexes of Pregabalin with weak cation ion exchange resins (KYRON T 134). The ion exchange 
complexes were prepared by the batch process using activated Kyron T 134 with a drug: resin ratios 
1:1, 1:2, 1:3 and 1:4 (% w/w). IR analysis, assay content and decomplexation studies confirmed 
complex formation. It was found that maximum complexation of drug with resin was noted between 
pH range 5.5-7, while activation of ion exchange resin does not affects the percent drug loading. 
Drug release from drug: resin complex in salivary pH was insufficient to impart bitter taste. A study 
on super-disintegrants along with directly compressible diluents is studied and its effect on 
disintegration time and enhance mouth feel. The prepared batches of tablets were evaluated for 
hardness, friability, drug content uniformity and in vitro dispersion time. Based on in vitro 
disintegration time (approximately 30 s), formulations were tested for in vitro drug release pattern (in 
0.06 N HCl), 
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Introduction 
Many patients find difficulty to swallow tablets and hard gelatin 
capsules, consequently they do not take medications as 
prescribed. It is estimated that 50% of the population is affected by 
this problem which results in a high incidence of incompliance and 
ineffective therapy [1]. For this reason the development of an orally 
disintegrating or rapidly disintegrating tablet (RDT) have recently 
interested  not only the pharmaceutical industry, but also academia 
[2] Actually RDT tablets are preferred by an increasing number of 
patients especially children and elderly, but also adult consumers 
who like to have their medication readily available at any time. 
Patients appreciate the convenience and the discreteness of these 
products which can be taken without water and which guaranty a 
rapid onset of action [3]. The European Pharmacopoeia adopted 
the term orodispersible tablet as a tablet to be placed in the mouth 
where it disperses rapidly before swallowing and which 
disintegrates in less than 3 min. There was no specification 
concerning neither the hardness nor the friability of this kind of 
tablets. That is why we find certain RDT in the market that 
disintegrate in less than 1 min or maybe 30 s. but are brittle and 
require specified peel able blister packaging and thus higher costs 
[4].Commercially available RDT are prepared by various 
techniques [5], mainly lyophilisation [6,7], molding and direct 
compression [8]. The lyophilisation and molding techniques 
produce RDT which disintegrate within about 30 s, but that have 
low physical resistance and high friability. On the other hand, 
tablets obtained by direct compression are less friable but 
disintegrate in a longer time [9].  
Attempts were made in order to decrease the disintegration time of 
RDT that have sufficient hardness prepared by direct compression 
[10]. Bi et al. [11] and Watanabe et al, [12] used microcrystalline 
cellulose (MCC) and low-substituted hydroxypropyl cellulose (L-
HPC) as disintegrants to prepare RDT by direct compression. 
According to the authors the ratios of these two disintegrants 
MCC/L-HPC in the range of 8:2ă9:1 resulted in tablets with the 
shortest disintegration times. While Bi et al. [11] used a wet 
compression method where wet granules of đ-lactose monohydrate 
were compressed and then the formed wet tablets were dried at 60 
◦C and kept in a desiccator for 12 h at room temperature.  Formed 
RDT showed a disintegration time of less than 30 s and a hardness 
of 0.5MPa.Thus the first part of our study consisted of the 
preparation of taste masked complex of the active principal and 
ionexchange resin and the evaluation of the complex using XRD. 
Thereafter, the second part of the study encompassed the 
preparation of tablets to evaluate the potential of compressing 
prepared complex using different excipient. The potential of 
addition of croscarmellose sodium, sodium starch glucolate and 
crosspovidone [12] as a disintegrating agent was also evaluated. 
Finally, the technological characteristics of the prepared tablets 
were evaluated in order to find the formula with the least time of 
disintegration and friability and eventually the best hardness. 
Pregabalin is an anticonvulsant drug used for neuropathic pain and 
as an adjunct therapy for partial seizures with or without secondary 
generalization in adults [13]. In general, emesis is preceded with 
nausea and in such condition it is difficult to administer drug with a 
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glass of water; hence it is beneficial to administer such drugs as 
ODTs. Pregabalin is an intensely bitter drug; hence, if it is 
incorporated directly into an ODT the main objective behind 
formulation of such a dosage form will definitely get futile.  
Ion exchange resins have been used as drug carriers in 
pharmaceutical dosage forms for taste masking [14]. Ion exchange 
resins are cross linked water-insoluble polymers carrying ionizable 
functional groups. Drugs can be loaded into an ion exchange resin 
by an exchanging reaction, and hence a drugăresin complex is 
formed [15]. Drug is released from the resinate by exchanging with 
ions in the gastro-intestinal fluid, followed by drug diffusion [16]. 
There are  literature reports on the interaction of amine drugs with 
polycarboxylic acid ion- exchanged resin[14, 17] that indicated 
these resins might be very useful in the taste masking. One study 
indicated that saliva, with an average pH of 6.7 and a cation 
concentration of 40 meq/L, would only elute a few percent of drug 
from polycarboxylic acid resin adsorbate [18]. Thus in the present 
study an attempt has been made to mask the taste of Pregabalin 
and to formulate ODTs with good mouth feel so as to prepare a 
„patient-friendly dosage form.‰ 
Material and Methods  
Materials 
Pregabalin was a gift from Glenmark pharmaceuticals (Mumbai). 
KYRON T 134 was a gift from Corel Pharma-Chem. Ahmedabad, 
India. Sodium starch glycolate, Croscarmellose sodium, 
Crospovidone Mannitol and silicified microcrystalline cellulose were 
provided as gift samples by Signet chem.. and flavor of Firmenich 
were provided by Manish global. All other chemicals used in the 
study were of analytical grade. 
Method 
Purification of ion exchange resin KYRON T 134 was washed with 
distilled water. The wet resin was activated by 0.1 M HCl 300 ml 
followed by washing with distilled water and was dried overnight in 
hot air oven at 50ĈC and was stored in an air tight container [19]. 
Preparation of Pregabalin resinate  
Pregabalin resinate was prepared using a batch process. For 
preliminary study, we optimized the ratio of resin to drug at 1:3. 
Drug (5.0 g) Resin (15.0 g) was placed in an glass beaker and then 
380 ml of distilled water was added. The mixture was stirred in the 
water bath at 37ĈC. The supernatant was collected and assayed at 
a wavelength of 210 nm (using HPLC) to determine the drug-
loading equilibrium time. Then, the Pregabalin resinates were 
separated from the filtrates by filtration, washed several times with 
distilled water, dried overnight at 50ĈC and kept in air tight 
container [19,22]. 
Characteristics of Pregabalin resinates 
Pregabalin content 
Pregabalin resinate (equivalent to 300 mg of Pregabalin) was 
placed in a beaker to which 0.06 N HCl (50 ml) was added for 
eluting Pregabalin from the resinate. The eluate was decanted and 
replaced with the same volume of fresh eluent. The volume of 
eluate was measured and assayed for the content of Pregabalin at 
a wavelength of 210 nm (using HPLC). The elution process was 
stopped when the absorbance of the last eluate was lower than 
0.01. The sum of the content of Pregabalin in each eluate was 
equal to the total content of Pregabalin in resinate. (Table 1) 
In vitro taste Evaluation 
In vitro taste was evaluated by determining drug release in 
simulated salivary fluid (SSF) (pH 6.8) to predict release in the 
human saliva. Solid drug: resin complex equivalent to 100 mg of 
drug was subjected to release rate study. Weighed quantity added 
to 10 ml phosphate buffer pH 6.8 Aliquot was withdrawn after 2 
min. The sample was filtered through 0.45øm milipore filter. The 
absorbance was measured at a wavelength of 210 nm (using 
HPLC)  (Table 1). 
 
Table 1. Drug content and in vitro taste evaluation of drug resin 
complex in simulated salivary fluid 
Ratio of drug :resin 
complex 
1: 2 1: 3 1: 4 
Assay of drug resin 
complex 90.12 99.8 99.9 
% Drug dissolved 
in SSF after Time  
2min* 
10. 0μ0.314 1.110μ0.112 0.764μ0.17 
Assay of pure 
drug 
99.9
 
Molecular Properties 
 Molecular properties on complexation were studied by x-ray 
powder diffraction (XRPD). The X-ray powder diffractograms of the 
Drug: KYRON T 134 (1:4), Pregabalin, and KYRON T 134 were 
recorded. using a Philips PW 1729 X-ray diffractometer (Legroupe 
Interconnection, Saint Jurie, Clubac, Canada) with monocrotized 
Cu Kđ radiation (1.314 A0), at a speed of 2θ mină1 from 10- to 60-
(2θ) under the voltage and current of 40 Kv and 30 Kv respectively 
(Figure 1,2 & 3).  
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Selection of Superdisintegrant and Formulation of ODTs 
Before formulation of tablets, the best superdisintegrant among 
Sodium starch glycolate, Croscarmellose sodium and 
Crospovidone was screened out (Table 2). The best 
superdisintegrant screened was used for the final formulation of 
tablets (Table 3). Tablets were prepared in various batches 
containing a blend of mannitol, microcrystalline cellulose and 
sorbitol (directly compressible) diluents and superdisintegrant in 
various concentrations (Table 4). Tablets were prepared by direct 
compression using 8.0 mm round for 25 mg and 13.0 mm for 100 
mg, standard concave beveled edge punch. 
 
                                                   Table 2. Selection of superdisintegrant 
Sr no Batch Disintegrant %/ tab Disintegration Time (Sec)*
1 D1 -- 150.0μ5.00
2 D2 
Cros Carmellose sodium 
3 70.36μ1.04
3 D3 5 55.95μ2.62
4 D4 7 50.26μ2.53
5 D5 
Sodium Starch Glycollate 
3 78.16μ2.04
6 D6 5 59.95μ2.57
7 D7 7 55.7μ3.79 
8 D8 
Cros Povidone 
3 50.05μ1.22
9 D9 5 35.30μ1.48
10 D10 7 30.73μ2.45
 
                                                  Table 3. Optimization of disintegration 
Sr no Batch  Disintegrant Quantity mg / tab Disintegration Time (Sec)*
1 D8 
Cros Povidone 
4 50.05μ1.22
2 D9 6 35.30μ1.48
3 D10 8 31.30μ2.45
4 D11 5 43.30μ1.67
5 D12 7 31.40μ1.82
6 D13 10 38.20μ3.78
 
                                                  Table 4. Formulation composition for an ODT 
Sr no Ingredient / tablet Formulation 
     F1 F2  F3  F4  F5  F6  F7 F8 
1 Drug resin complex 400.0 400.0 400.0 400.0 400.0 400.0 400.0 400.0 
2 Mannitol SD 200 184.6 - - 27.0 - 10.0 10.0 110.0 
3 Sorbitol -  184.6 - 110.0 27.0 117.0 127.0 27.0 
4 MCC (Avicel 112)  - - 184.6 - 110.0 10.0 - - 
5 Starch 1500  - - - 47.6 47.6 47.6 47.6 47.6 
6 PVP K-30 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 
7 Crosspovidone 49.0 49.0 49.0 49.0 49.0 49.0 49.0 49.0 
8 Sucralose 20.0 20.0 20.0 20.0 20.0 20.0 20.0 20.0 
9 Mint 20.0 20.0 20.0 20.0 20.0 20.0 20.0 20.0 
10 Colloidal silicon dioxide 8.2 8.2 8.2 8.2 8.2 8.2 8.2 8.2 
11 Magnesium stearate 8.2 8.2 8.2 8.2 8.2 8.2 8.2 8.2 
*- Drug resin complex (DRC) equivalent to 100 mg of Pregabalin. 
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Physical Properties of the Tablet Blend  
Physical properties such as bulk density, tapped density, 
compressibility index, and the angle of repose of blend were 
determined (Table 5). Bulk density was determined by the USP 
method I; tapped density was determined by USP method II. 
Percent compressibility was calculated using Equations 1. Percent 
compressibility = {( D t î D b ) / D t } ï 100 ⁄⁄⁄⁄⁄(1) 
Where, Dt and Db are tapped and bulk densities [20]. 
 
Table 5. Physical properties of tablet blend 
Batch 
No 
Bulk 
density 
(g/mL) 
Tapped 
density 
(g/mL) 
Angle of 
Repose* 
(Ĉ) 
% 
Comp
ressib
ility 
Haus
ner 
ratio 
F1 0.58 0.68 26.56μ0.70 14.71 1.18 
F2 0.57 0.67 25.45μ0.60 14.93 1.18 
F3 0.48 0.64 27.13μ0.78 25.00 1.33 
F4 0.56 0.65 26.5μ0.67 13.85 1.16 
F5 0.52 0.66 26.45μ0.85 21.21 1.27 
F6 0.54 0.65 25.25μ0.54 16.92 1.20 
F7 0.56 0.66 27.61μ0.63 15.15 1.18 
F8 0.56 0.65 26.21μ0.43 13.85 1.16 
Evaluation of Tablet 
The prepared orodispersible tablets were evaluated for hardness, 
weight variation, thickness, friability and drug content (Table 6) 
[21]. Hardness of the tablets was tested using a Strong- Cobb 
hardness tester (Tabmachine, Mumbai, India). Friability of the 
tablets was determined in a Roche friabilator (Campbell 
Electronics, Mumbai, India). The thickness of the tablets was 
measured by vernier calliper. Weight variation test was performed 
according to the official method as per USP. 
In Vitro Disintegration Time 
In vitro disintegration time for RDTs was determined using USP 
and disintegration of tablet in a beaker containing 50 ml of SSF. 
The volume of the media will give a discriminatory nature to the 
disintegration time. 
Table 6. Physical properties of tablet 
Batch 
No. 
Friability Hardness 
(Kg/cm2) 
Thickness % Weight 
variation 
Disintegr
ati 
on time 
(Sec) 
F1 0.72 μ 0.19 10.13μ0.24 5.40 μ 0.05 700.20μ 1.70 55.0μ 2.2
F2 0.65 μ 0.2 10.30μ0.24 5.40 μ 0.02 700.50μ 1.80 52.0μ 3.0
F3 0.89 μ 0.14 7.50μ0.24 5.39 μ 0.04 700.00μ 1.20 30.0μ 4.0
F4 0.70 μ 0.59 10.50μ0.20 5.48 μ 0.06 700.70μ 1.35 35.0μ 4.0
F5 0.66 μ 0.32 7.50μ0.30 5.40 μ 0.03 700.70μ 1.40 32.0μ 1.0
F6 0.59 μ 0.24 10.00μ0.32 5.39 μ 0.07 700.20μ 1.80 35.0μ 4.0
F7 0.68 μ 0.18 10.70μ0.25 5.39 μ 0.03 700.15μ 1.50 40.0μ 4.0
F8 0.56 μ 0.29 11.20μ0.40 5.38 μ 0.02 700.10μ 1.50 38.0μ 2.0
In-vitro Dissolution studies 
The in-vitro dissolution studies were carried out using USP 
apparatus type II (paddle) at 50 rpm. 
The dissolution medium used was 0.06 N HCl (900 ml) maintained 
at 37 μ 0.5ĈC. Aliquots of dissolution media were withdrawn at 
different intervals and content of Pregabalin was measured at a 
wavelength of 210 nm (using HPLC). The dissolution experiments 
were conducted in triplicate. Results were shown in figure 4, 5 and 
6. 
 
Figure  4. In-vitro release profile of capsule of marketed product 
and batches F1 & F2 
Figure  5. In-vitro release profile of capsule of marketed product 
and batches F3 TO F5 
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Figure  6. In-vitro release profile of capsule of marketed product 
and batches F6 TO F8 
Comparison of Optimized Formulation with Marketed 
Capsule 
 In vitro Dissolution studies for optimized formulation and Marketed 
Capsule were also carried out (Figure 6). 
Results and Discussion  
Characterization of DRCs (Drug resin complex) 
Percentage drug loading in DRCs was found from 96.12 to 99.9. 
No drug release was observed in SSF from complexes with the 
drug-polymer ratio of 1:3 and ratios with lesser drug, therefore, the 
ratio 1:3 was considered the optimal DRC with complete masking 
of bitter taste for further studies. The x-ray diffractogram of 
Pregabalin confirms its crystalline nature, as evidenced from the 
number of sharp and intense peaks (Figure 1). The diffractogram of 
resin (KYRON T 134) showed diffused peaks, indicating its 
amorphous nature (Figure 2). However, the diffraction pattern of 
DRC (1:3) represents complete disappearance of crystalline peaks 
of drug (Figure 3). These finding suggest the formation of new solid 
phase with a lower degree of crystallinity due to complexation .  
Selection of the Superdisintegrant 
The formulation of orordispersible tablet was made by using 
Pregabalin- resin complex. Batches D1 to D10 were prepared by 
direct compression to select the disintegrant, from the results 
shown in Table 2, it can be concluded that the tablets containing 
crospovidone (D8 ă D10) exhibit quick disintegration time and 
followed by croscarmellose sodium and sodium starch glycolate. 
The probable reason for delayed disintegration time of the tablets 
might be slow water uptake or more felling tendency of 
croscarmellose sodium and sodium starch glycolate than 
crospovidone or gel formation at higher percentage. Hence 
crospovidone was selected as a disintegrant for the further studies. 
From the results shown in Table 3 is obvious that the maximum 
concentration of crospovidone might be less than 10%. Batches D8 
- D13, were prepared to optimize the optimum concentration of 
crospovidone in order to obtained rapid disintegration at minimum 
concentration. The composition and results of batches are shown 
in Table 4. Batch D10 had shown more decrease in disintegration 
time but not more efficient then D12, on further increasing the 
concentration as in batch D13 there was increase in disintegration 
time for this reason batch S12 was selected so as to avoid any 
delay in disintegration time due to increase in disintegrant. 
Sometimes increase in disintegrant concentration decreases 
disintegration time, such behaviour of superdisintegrant may be 
due to the blockade of capillary pores which prevents the entry of 
fluid into the tablet. 
Physical Properties of the Tablet Blend 
The tablet blend of all the batches was evaluated for different 
derived properties viz- angle of repose (between 25 to 27), bulk 
density (between 0.48 to 0.57 gm/cm3), Compressibility index 
(between 13 to 25). The results angle of repose and compressibility 
indicated that the flowability of blend is significantly good. All the 
tablets passed weight variation test as the percent weight variation 
was within the pharmacopoeial limits. Hardness was shown in the 
range of 7.50μ0.24 to 11.20μ0.40 Kg/cm2 in all the formulations. 
The hardness of all tablets was kept within the above mentioned 
range to compare the disintegration time between the formulations 
prepared using different disintegrants and their varying 
concentrations. The friability of all formulations was determined. 
The friability values of none of the formulations exceeded 1%. The 
results of friability indicate that the tablets were mechanically stable 
and can withstand rigors of transportation and handling. Thickness 
of all tablets was between 5.38μ0.02 ă5.48 μ 0.06 mm showing 
fairly uniform tabletting. The results of disintegration of all the 
tablets were found to be within prescribed limits and satisfied the 
criteria of Orodispersible tablet. The values were found to be in the 
range of 32.0μ 1.0 to 55.70 μ 2.2 sec. The time intensity study for 
taste in human volunteers of both the DRC and ODT revealed 
considerable masking of the bitter taste of Pregabalin with degree 
of bitterness below the threshold value (0.5) ultimately reaching to 
0 within 15 minutes. Sensory evaluation of the optimized tablet 
proved good palatability. 
Drug Release from ODT 
All the tablets prepared were subjected for release profile. The 
tablets prepared from crospovidone i.e. F1 to F8 showed a drug 
release upto 100% (Figure 4, Figure 5 and Figure 6) (Table 7a and 
7b). Among eight batches, batch F8 which contain sorbitol and 
Mannitol along with crospovidone was selected as optimized batch 
because of its lowest disintegration time and highest drug release. 
The drug release of the marketed product and F8 formulation was 
found to be 100 μ 1.52 and 100.0 μ 1.68 at the end of 20 minutes. 
From the above observations, it may be concluded that optimized 
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formulation is better or as good as an marketed conventional 
capsule in release rate of drug with taste masked characteristic. 
Conclusion 
The study conclusively demonstrated complete taste masking of 
Pregabalin, rapid disintegration and dissolution of ODT. Taste 
masking and rapid disintegration of tablets formulated in this 
investigation may possibly help in administration of Pregabalin in a 
more palatable form without water during emesis. Thus, the 
„patient-friendly dosage form‰ of bitter drugs, especially for 
pediatric, geriatric, bedridden, and non co-operative patients, can 
be successfully formulated using this technology. 
. 
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